News

NASDAQ: ABVC

Press Releases

ABVC BioPharma Records $100,000 Licensing Milestone From ForSeeCon, Strengthening Eye Health Program

 ABVC BioPharma Records $100,000 Licensing Milestone From ForSeeCon, Strengthening Eye Health Program 150 150 Press Release
  • Press Release

ABVC BioPharma Records With Total Milestone Payments Reaching $946,000, ABVC Deepens Its Ophthalmology Focus Through a High-potential Partnership With ForSeeCon SILICON VALLEY, CA – July 18, 2025 (NEWMEDIAWIRE) – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today announced the receipt of a $100,000 milestone licensing payment from ForSeeCon Eye Corporation. The milestone marks continued progress under the licensing agreement to develop and commercialize drugs for ophthalmic indications. This payment adds to ABVC’s cumulative licensing revenue, which now totals $946,000 across its strategic partnerships with AiBtl, OncoX, and ForSeeCon. Combining…

ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology

 ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology 150 150 Press Release

SILICON VALLEY, CA – June 26, 2025 (NEWMEDIAWIRE) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, proudly announces that a podcast with Biotech Orbit (https://youtu.be/TYrNEA0mG-8?si=xnCCjK1ZrRIw8OK7), featured the Company’s Chief Executive Officer, Dr. Uttam Patil, among their list of the most influential Indian-origin CEOs leading major global organizations. On the podcast, Dr. Patil discussed the Company’s flagship antidepressant candidate, ABV-1504, which is preparing to enter Phase III clinical trials. In the interview, Dr. Patil emphasized a critical differentiator found thus far in in-house trials of ABV-1504 – the absence of…

ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment

 ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment 150 150 Press Release

SILICON VALLEY, CA – June 24, 2025 (NEWMEDIAWIRE) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it has converted its initial $100,000 convertible note into 10,000 shares of common stock of AiBtl BioPharma Inc. at a conversion price of $10 per share. The conversion price is supported by an independent third-party valuation report, which estimated the current fair value of AiBtl’s equity. In addition, ABVC disclosed its intention to invest up to $20 million in AiBtl over time, further reinforcing its role as a lead strategic investor. ABVC expects that AiBtl will utilize…

Integrating Botanical Drugs into Western Medicine

 Integrating Botanical Drugs into Western Medicine 150 150 ABVC

https://www.youtube.com/watch?v=TYrNEA0mG-8 In this episode of Biotech Orbit, host Victor Lee speaks with our CEO, Dr. Utam Patil. Here he discusses our botanical-based therapies for major depressive disorder (MDD) and cancer. The conversation explores the unique advantages and regulatory challenges of botanical drugs, which are derived from natural plant and fungal sources. Dr. Patil shares that ABVC’s lead candidate for MDD, ABV-1504, is entering a Phase 3 clinical trial and has shown no signs of suicidal ideation or addiction which is a common concerns with synthetic antidepressants. This positions ABV-1504 as a promising alternative, particularly since it functions as a single…

ABVC BioPharma Announces Board Approval of Share Dividend Showing Confidence in Subsidiary Growth and Long-Term Shareholder Value

 ABVC BioPharma Announces Board Approval of Share Dividend Showing Confidence in Subsidiary Growth and Long-Term Shareholder Value 150 150 Press Release

Silicon Valley, CA – (NewMediaWire) – June 03, 2025 – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that its Board of Directors approved a plan to distribute, one share of stock of AiBtl BioPharma Inc. (“AIBTL”), a corporation organized and existing and under the laws of the State of Delaware, as a dividend reward to its shareholders for each share of ABVC common stock owned by the shareholder (the “AIBTL Shares”). Based on the Company’s current holdings, the Company expects to distribute approximately 15M AIBTL Shares.…

2024 ABVC Investor Presentation

View the latest product information, status updates, financial information, and more.

VIEW PRESENTATION
PRESS RELEASES
SEC FILINGS
INVESTOR CONSIDERATIONS
CONTACT ABVC
SAFE HARBOR STATEMENT

With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of ABVC could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company’s operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by ABVC, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

Investor Considerations

  • Strong portfolio of medicines and medical devices addresses wide range of disorders.
  • In 2022, Vitargus is expected to begin a global pivotal trial, the final step leading to marketing in collaboration with big pharma licensing partners.
  • MDD drug intended to reduce adult depression completes Clinical Phase II with results exceeding expectations.
  • Botanical expertise leads to medicines with fewer side effects.
  • Partnerships with some of the most prestigious researchers in the world enhances the value of clinical trial results.
  • Business model designed to minimize burn rate.
  • Less than 30 million shares outstanding.

BACKGROUND

Leadership Team

MANAGEMENT
ADVISORY

NASDAQ: ABVC

Latest News

ABVC NEWSROOM

THERAPEUTIC FOCUS

Retinal Vitrectomy

Vitargus® – ABV-1701
Contact ABVC & Stay Informed

Contact ABVC BioPharma

SOCIAL MEDIA

Facebook

LinkedIn

TELEPHONE

+1 845-291-1291

EMAIL

info@abvcpharma.com

44370 Old Warm Springs Boulevard
Fremont, California 94538 USA
CONTACT FORM

Copyright ©2023 ABVC BioPharma, Inc. All Rights Reserved.

   

Enter your
search terms here.